ASH Annual Meeting and Exposition | Conference

Dr. Landgren on Combinations in Newly Diagnosed Myeloma

December 16th 2013

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

December 16th 2013

MarÃa-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

Dr. Berenson on a Study of Pomalidomide in R/R Myeloma

December 13th 2013

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Idelalisib Improves Survival in High-Risk CLL

December 13th 2013

Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.

Quizartinib Active in AML at Lower Doses

December 13th 2013

Almost half of patients with relapsed/refractory AML had complete remissions when treated with quizartinib, which also had a more favorable safety profile as compared with higher doses.

Dr. Goy on CAR-Modified T Cells in Lymphoma

December 13th 2013

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

December 12th 2013

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Dr. Shah on Novel Therapies for Multiple Myeloma

December 11th 2013

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

Latest Data Further Support Ibrutinib's Efficacy in CLL

December 11th 2013

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

Dr. Furman on Avoiding Chemotherapy With Idelalisib

December 10th 2013

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Telomerase Inhibitor Imetelstat Shows Promise in Myelofibrosis

December 10th 2013

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

New Drug Class Shows Activity in Refractory Multiple Myeloma

December 10th 2013

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL

December 10th 2013

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

December 10th 2013

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

December 9th 2013

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

Ibrutinib Induces Rapid, Durable Responses in WaldenstrÃ¶m's Macroglobulinemia

December 9th 2013

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory WaldenstrÃ¶m's macroglobulinemia, and the responses to ibrutinib were durable.

IPI-145 Has Activity in Relapsed/Refractory CLL

December 9th 2013

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL

December 9th 2013

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.

Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma

December 9th 2013

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Obinutuzumab Regimen Slows CLL Compared With Rituximab

December 9th 2013

Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.